EXHIBIT 99.1


TUESDAY, JULY 29, 2003, 8:00 AM EASTERN TIME

PRESS RELEASE

SOURCE: Isolagen, Inc.

ISOLAGEN IN PHASE III TRIALS

HOUSTON, TX. - (PRNewswire) - July 29, 2003 - Isolagen, Inc. (AMEX:ILE)
announced today that the Company's Phase III trial for dermal defects has
commenced pursuant to an effective Investigational New Drug Application ("IND")
for the treatment of wrinkles and scars. The Phase III trial, being conducted in
ten sites, involves physicians who are either plastic surgeons or dermatologists
with practices that emphasize aesthetic procedures. The patients' enrollment has
been completed and totals one hundred fifty-two patients. To date, over 90% of
the patients have had their first consultation. The first patients are scheduled
to begin their injections in August 2003 with the final patient injection
scheduled for the end of September 2003. This Phase III trial is a double-blind
study with 75% of the patients receiving the therapeutic dosage and the
remaining 25% receiving a placebo.

In addition, in January of 2003, Isolagen commenced a double-blind Phase II
trial under the IND, which is a two-site dose ranging study of forty patients.
Isolagen expects to complete its analysis of the data from the Phase II trial
during the fourth quarter of 2003.

Isolagen also has a Phase I clinical trial of twenty-one patients in progress
for dental applications addressing gingival recession. Isolagen expects to
complete this study in the first quarter of 2004.

ABOUT ISOLAGEN, INC.

Isolagen, Inc. (AMEX:ILE) is the parent company of Isolagen Technologies, Inc.,
which was founded in 1995. Isolagen has focused its efforts in the development
of autologous cellular technology that has specific applications in cosmetic
dermatology and is exploring applications for periodontal disease,
reconstructive dentistry and other health-related markets.

Isolagen is an emerging pharmaceutical bioscience company specializing in the
development and commercialization of autologous cellular therapy for hard and
soft tissue regeneration and other therapies. Isolagen currently holds five
patents. Autologous cellular therapy is a process whereby a patient's own cells
are extracted, reproduced and then reintroduced to the patient for specific
cosmetic and medical applications. Unlike other applications for the treatment
of dermal defects, Isolagen utilizes only the patient's unique, living cells to
produce the patient's own collagen. There is no foreign substance utilized in
this treatment protocol. Isolagen's goal is to become the industry leader in the
research, development and commercialization of autologous cellular therapy.


                                       3



This press release contains forward-looking statements, including statements
addressing Isolagen's Phase II and Phase III trials relating to the treatment of
wrinkles and scars and Isolagen's Phase I trial relating to dental applications
addressing gingival recession, and general statements relating to the
development of autologous cellular therapy that has specific applications in
cosmetic dermatology and also relating to the exploration of applications for
periodontal disease, reconstructive dentistry and other health-related markets.
The discovery and development of applications for autologous cellular therapy
are subject to substantial risks and uncertainties. There can be no assurance
that Isolagen's trials relating to autologous cellular therapy applications for
the treatment of dermal defects or gingival recession can be conducted within
the timeframe that Isolagen expects, that such trials will yield positive
results, or that additional applications for the commercialization of autologous
cellular therapy can be identified and advanced into human clinical trials.
These and other factors, including, but not limited to those described in
Isolagen's most recent annual report on Form 10-KSB filed with the Securities
and Exchange Commission, could cause future results to differ materially from
the expectations expressed in this press release. The forward-looking statements
contained in this press release may become outdated over time. Isolagen does not
assume any responsibility for updating any forward-looking statements.

Isolagen's corporate headquarters are located in Houston, TX. For further
information, please see www.isolagen.com.

Contact:
Isolagen, Inc.
Michael Macaluso, CEO 713-780-4754
Jeffrey W. Tomz, CFO 713-780-4754


                                       4